Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the State of Georgia

Schizophrenia Bulletin

Volumn 30, Issue 4, 2004, Pages 983-995

  Miller, L Stephen ^a,b   Martin, Bradley C ^b  

^a University of Georgia ^*  (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Economics; Expenditures; Medicaid; Medicare; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMMUNITY MENTAL HEALTH CENTER; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; INSTITUTIONAL CARE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL INFORMATION SYSTEM; MEDICARE; MENTAL HEALTH SERVICE; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; SCHIZOPHRENIA; UNITED STATES;

EID: 16344395312     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a007147     Document Type: Article

References (26)

1. Andrews, G. The cost of schizophrenia revisited. Schizophrenia Bulletin, 17(3):389-394, 1991.
2. Davies, L.M., and Drummond, M.F. Economics and schizophrenia: The real cost. British Journal of Psychiatry, 165(Suppl):18-21, 1994.
3. Evers, S.M.A.A., and Ament, A.J.H.A. Costs of schizophrenia in The Netherlands. Schizophrenia Bulletin, 21(1):141-153, 1995.
4. Georgia Department of Human Resources, Division of Mental Health, Mental Retardation and Substance Abuse. FY95 Hospital Budget and Utilization Report by Region. Atlanta, GA: Georgia Department of Human Resources, 1995.
5. Georgia Department of Medical Assistance. Georgia Department of Medical Assistance Annual Report. Atlanta, GA: GDMA, 1992.
6. Georgia Department of Medical Assistance. Georgia Department of Medical Assistance Annual Report. Atlanta, GA: GDMA, 1994.
7. Hall, W.; Goldstein, G.; Andrews, G.; Lapsley, H.; Bartels, R.; and Silove, D. Estimating the economic costs of schizophrenia. Schizophrenia Bulletin, 11(4):598-610, 1985.
8. Health Care Financing Administration. "Statistical Tables." http://www.hcfa.gov/stats/indicatr/tables/t08.htm, 1998. Accessed 19 March 2001.
9. Hyman, S.E. The NIMH perspective: Next steps in schizophrenia research. Biological Psychiatry, 47:1-7, 2000.
10. Keith, S.J.; Regier, D.A.; and Rae, D.S. Schizophrenic disorders. In: Robins, L.N., and Regier, D.A., eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: Free Press, 1991. pp. 33-52.
11. Kendler, K.S.; Gallagher, T.J.; Abelson, J.M.; and Kessler, R.C. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a U.S. community sample. Archives of General Psychiatry, 53:1022-1031, 1996.
12. Lehman, A.F., and Steinwachs, D.M. Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophrenia Bulletin, 24(1):11-20, 1998a.
13. Lehman, A.F., and Steinwachs, D.M. Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24(1):1-10, 1998b.
14. Mark, T.; McKusick, D.; King, E.; Harwood, H.; and Genuardi, J. National Expenditures for Mental Health, Alcohol and Other Drug Abuse Treatment, 1996. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, 1996. Available at http://www.mental- health.org.
15. Martin, B.C., and Miller, L.S. Expenditures for treating schizophrenia: A population-based study of Georgia Medicaid recipients. Schizophrenia Bulletin, 24(3):479-488, 1998.
16. Martin, B.C.; Miller, L.S.; and Kotzan, J.A. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: Current trends and five-year time series forecasts. Schizophrenia Research, 47:281-292, 2001.
17. McDowall, D.; McCleary, R.; Meidinger, E.E.; and Hay, R.A. Interrupted Time Series Analysis. Thousand Oaks, CA: Sage Publications, 1980.
18. McEvoy, J.P.; Scheifler, P.L.; and Frances, A. The Expert Consensus Guidelines Series: Treatment of schizophrenia. Journal of Clinical Psychiatry, 60(Suppl 11):4-80, 1999.
19. McGuire, T.G. Measuring the economic costs of schizophrenia. Schizophrenia Bulletin, 17(3):375-388, 1991.
20. Murray, C.J.L., and Lopez, A.D., eds. The Global Burden of Disease. Boston, MA: Harvard University Press, 1996.
21. Revicki, D.A. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophrenia Research, 35:S101-S109, 1999.
22. Rice, D.P.; Kelman, S.; and Miller, L. Estimates of economic costs of alcohol and drug abuse and mental illness, 1985 and 1988. Public Health Reports, 106:280-292, 1991.
23. Rice, D.P., and Miller, L.S. The costs of schizophrenia: Assessing the burden. Psychiatric Clinics of North America, 16:413-423, 1993.
24. Rice, D.P., and Miller, L.S. The economic burden of schizophrenia: Conceptual and methodological issues and cost estimates. In: Moscarelli, M.; Rupp, A.; and Sartorius, N., eds. Schizophrenia: Handbook of Mental Health Economics and Health Policy. Vol. 1. New York, NY: John Wiley and Sons, 1996. pp. 321-334.
25. Rupp, A., and Keith, S.J. The costs of schizophrenia: Assessing the burden. Psychiatric Clinics of North America, 16:413-423, 1993.
26. U.S. Department of Health and Human Services. International Classification of Diseases, 9th Revision, Clinical Modification: ICD-9-CM. 3rd ed. Washington, DC: U.S. Department of Health and Human Services, Public Health Service, 1989.